🚀 VC round data is live in beta, check it out!
Largest BioTech Public Companies
Benchmark revenue and EBITDA valuation multiples for public comps like
Eli Lilly, Johnson & Johnson, AbbVie, Roche and Novartis.
 | $1,018 | +23% | $909B | $944B | 13.7x | 29.7x | ||
| $240 | +45% | $577B | $605B | 6.3x | 17.1x | ||
| $234 | +12% | $414B | $476B | 7.6x | 18.0x | ||
 | $59 | +43% | $377B | $400B | 5.0x | 12.7x | ||
| $166 | +33% | $316B | $339B | 6.2x | 14.7x | ||
| $121 | +35% | $300B | $335B | 5.1x | 12.0x | ||
 | $94 | +25% | $291B | $316B | 5.3x | 15.2x | ||
| $386 | +24% | $208B | $253B | 6.9x | 13.6x | ||
| $509 | +2% | $191B | $220B | 4.9x | 19.6x | ||
| $150 | +34% | $186B | $202B | 6.8x | 12.8x | ||
 | $37 | -45% | $166B | $182B | 3.8x | 7.9x | ||
| $27 | +5% | $151B | $202B | 3.2x | 8.4x | ||
| $206 | +1% | $146B | $161B | 6.5x | 20.6x | ||
| $62 | +2% | $127B | $163B | 3.4x | 9.5x | ||
| $486 | +0% | $123B | $119B | 9.7x | 22.0x | ||
| $29 | +49% | $117B | $136B | 3.0x | 8.9x | ||
 | $44 | -20% | $107B | $121B | 2.2x | 7.5x | ||
 | $64 | +49% | $105B | $99B | 12.0x | 23.6x | ||
| $791 | +25% | $84B | $78B | 5.3x | 14.9x | ||
 | $146 | 0% | $63B | $74B | 3.0x | 10.6x | ||
| $36 | +31% | $58B | $83B | 2.9x | 10.8x | ||
 | $288 | +53% | $55B | $56B | 6.0x | 17.6x | ||
| Pet Care+1 | $129 | -22% | $54B | $61B | 6.4x | 14.7x | |
 | $1,158 | +10% | $54B | $53B | 16.4x | 29.9x | ||
 | $8 | +11% | $53B | $47B | 9.6x | 32.8x | ||
 | $105 | -41% | $51B | $61B | 3.9x | 11.4x | ||
| $637 | +52% | $51B | $51B | 11.7x | 33.5x | ||
| $5 | +2% | $48B | $57B | 3.8x | 14.8x | ||
| $676 | -2% | $47B | $52B | 6.0x | 18.9x | ||
| $764 | +31% | $47B | $43B | 9.4x | 33.0x | ||
| $47 | +84% | $46B | $84B | 1.6x | 7.5x | ||
 | $19 | +2% | $46B | $43B | 6.9x | 23.6x | ||
| $188 | +58% | $44B | $47B | 8.6x | 36.0x | ||
| $325 | +20% | $43B | $41B | 10.1x | 51.6x | ||
| $14 | +45% | $42B | $38B | 5.7x | 12.1x | ||
| $85 | -10% | $41B | $45B | 4.3x | 16.9x | ||
 | $33 | +120% | $39B | $52B | 3.1x | 9.9x | ||
| $26 | +2% | $38B | $37B | 6.8x | 17.5x | ||
| $86 | +83% | $37B | $41B | 3.7x | 16.7x | ||
| $165 | +48% | $36B | $37B | 12.5x | 33.7x | ||
| $79 | -2% | $36B | $42B | 2.0x | 11.3x | ||
| $25 | +11% | $35B | $32B | 5.8x | 46.9x | ||
| $66 | +35% | $35B | $33B | 2.0x | 9.0x | ||
| $18 | -16% | $34B | $32B | 2.4x | 11.9x | ||
| $118 | +1% | $33B | $35B | 5.0x | 17.0x | ||
| $58 | +28% | $33B | $45B | 1.7x | 10.4x | ||
| $150 | +97% | $32B | $31B | 37.6x | (29.2x) | ||
 | $267 | +237% | $31B | $31B | 2.3x | 26.0x | ||
| $307 | -17% | $30B | $31B | 8.0x | 23.6x | ||
| $174 | -1% | $30B | $43B | 2.6x | 11.3x | ||
| $16 | +72% | $28B | $31B | 2.3x | 8.6x | ||
| $200 | +42% | $28B | $27B | 11.4x | (102.8x) | ||
| $188 | +37% | $28B | $30B | 3.1x | 9.9x | ||
| $1,325 | +12% | $27B | $29B | 7.1x | 22.9x | ||
| $4 | +40% | $26B | $22B | 10.2x | 26.6x | ||
| $5 | +103% | $26B | $23B | 8.6x | 17.5x | ||
| $286 | +23% | $24B | $30B | 2.1x | 12.2x | ||
| $210 | +24% | $23B | $29B | 2.6x | 13.2x | ||
| $91 | 0% | $23B | $6B | 2.0x | (5.0x) | ||
| $490 | +59% | $21B | $18B | 5.7x | 10.7x | ||
| $54 | +90% | $21B | $17B | 8.5x | (5.9x) | ||
 | $3 | -3% | $21B | $18B | 4.2x | 14.0x | ||
| $5 | +43% | $20B | $19B | 5.9x | 16.0x | ||
| $47 | +53% | $20B | $28B | 8.5x | 9.3x | ||
| $133 | +68% | $20B | $21B | 4.8x | 17.2x | ||
| $207 | -1% | $20B | $23B | 6.4x | 20.7x | ||
| $28 | +178% | $20B | $16B | 1540.8x | (13.5x) | ||
| $101 | +186% | $20B | $18B | 1564.8x | (14.3x) | ||
| $100 | +65% | $20B | $16B | 3.1x | 10.1x | ||
| $104 | +139% | $20B | $21B | 6.4x | 48.0x | ||
| $22 | +58% | $19B | $15B | 4.9x | 11.6x | ||
| $69 | +11% | $18B | $18B | 15.8x | 48.0x | ||
| $11 | +77% | $18B | $17B | 8.3x | 60.6x | ||
| $29 | +51% | $18B | $22B | 5.7x | 18.8x | ||
| $16 | +80% | $18B | $32B | 2.2x | 7.5x | ||
| $42 | +24% | $17B | $17B | 50.7x | (449.1x) | ||
| $8 | -27% | $17B | $21B | 4.8x | 14.8x | ||
| $243 | -7% | $17B | $17B | 6.1x | 25.8x | ||
| $75 | +22% | $17B | $17B | 4.1x | 12.5x | ||
| $242 | +9% | $17B | $21B | 5.0x | 16.8x | ||
 | $34 | +21% | $16B | $13B | 3.9x | 10.1x | ||
| $48 | +37% | $16B | $16B | 11.4x | 34.7x | ||
| $104 | +34% | $16B | $18B | 2.5x | 6.3x | ||
| $82 | -3% | $16B | $18B | 4.4x | 13.9x | ||
| $190 | +55% | $16B | $15B | 3.3x | 8.6x | ||
| $18 | +3% | $15B | $14B | 7.1x | 41.4x | ||
| $242 | +55% | $15B | $15B | 14.9x | 1613.7x | ||
| $277 | +16% | $15B | $15B | 79.0x | 126.5x | ||
| $24 | -17% | $15B | $15B | 10.0x | 30.2x | ||
| $8 | 0% | $15B | $13B | 2.1x | 14.3x | ||
 | $42 | +35% | $14B | $16B | 4.9x | 12.5x | ||
| $1 | +94% | $14B | $13B | 3.0x | 11.2x | ||
 | $78 | +38% | $14B | $18B | 2.0x | 9.0x | ||
| $117 | -12% | $14B | $14B | 2.9x | 11.7x | ||
| $342 | +28% | $13B | $13B | 9.1x | 47.6x | ||
 | $1 | +57% | $13B | $12B | 2.5x | 8.8x | ||
| $133 | +21% | $13B | $12B | 4.1x | 18.5x | ||
| $82 | +172% | $13B | $13B | 13.6x | (31.8x) | ||
| $4 | +32% | $13B | $13B | 3.7x | 8.9x | ||
| $457 | +50% | $13B | $13B | 4.9x | 22.1x |
Financial data powered by FactSet and Morningstar. Valuation multiples as of last 12 months. For more data, start your free trial here.
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.